Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:
USARx offers the following ways to purchase this medication. Choose the Best option for you!
Pay this amount and pick up your prescription at ANY Retail pharmacy of your choice! Walgreens, CVS, Walmart, etc.
The easiest way to receive your medications.
Ciprofloxacin is a fluoroquinolone (flor-o-KWIN-o-lone) antibiotic that fights bacteria in the body. It is used to treat different types of bacterial infections, including skin infections, bone and joint infections, respiratory or sinus infections, urinary tract infections, and certain types of diarrhea. It is also used to treat gonorrhea.
Ciprofloxacin is also used to treat people who have been exposed to anthrax or certain types of plague.
Ciprofloxacin should be used only for infections that cannot be treated with a safer antibiotic.
Fluoroquinolone antibiotics can cause serious or disabling side effects that may not be reversible, such as tendon rupture or nerve problems.
Ciprofloxacin can cause serious side effects, including tendon problems, nerve damage, serious mood or behavior changes, or low blood sugar.
Stop using this medicine and call your doctor at once if you have symptoms such as: headache, hunger, irritability, numbness, tingling, burning pain, confusion, agitation, paranoia, problems with memory or concentration, thoughts of suicide, or sudden pain or movement problems in any of your joints.
In rare cases, ciprofloxacin may cause damage to your aorta, which could lead to dangerous bleeding or death. Get emergency medical help if you have severe and constant pain in your chest, stomach, or back.
You may not be able to use ciprofloxacin if you have a muscle disorder. Tell your doctor if you have a history of myasthenia gravis.
You should not use ciprofloxacin if you are allergic to it, or if:
you also take tizanidine; or
you are allergic to other fluoroquinolones (gemifloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin, and others).
You also take theophylline
Ciprofloxacin may cause swelling or tearing of a tendon (the fiber that connects bones to muscles in the body), especially in the Achilles' tendon of the heel. This can happen during treatment or up to several months after you stop taking this medicine. Tendon problems may be more likely in certain people (children and older adults, or people who use steroid medicine or have had an organ transplant).
To make sure this medicine is safe for you, tell your doctor if you have ever had:
tendon problems, bone problems, arthritis, or other joint problems (especially in children);
blood circulation problems, aneurysm, narrowing or hardening of the arteries;
heart problems, high blood pressure;
a genetic disease such as Marfan syndrome or Ehler's-Danlos syndrome;
diabetes;
a muscle or nerve disorder, such as myasthenia gravis;
kidney disease;
seizures or epilepsy;
a head injury or brain tumor;
long QT syndrome (in you or a family member); or
low levels of potassium in your blood (hypokalemia).
Do not give this medicine to a child without medical advice.
It is not known whether this medicine will harm an unborn baby. Tell your doctor if you are pregnant.
You should not breast-feed while using this medicine.
Take ciprofloxacin exactly as prescribed by your doctor. Follow all directions on your prescription label and read all medication guides or instruction sheets.
You may take ciprofloxacin with or without food, at the same time each day.
Shake the oral suspension (liquid) for 15 seconds before you measure a dose. Use the dosing syringe provided, or use a medicine dose-measuring device (not a kitchen spoon). Do not give ciprofloxacin oral suspension through a feeding tube.
Swallow the extended-release tablet whole and do not crush, chew, or break it.
Use ciprofloxacin for the full prescribed length of time, even if your symptoms quickly improve. Skipping doses can increase your risk of infection that is resistant to medication. This medicine will not treat a viral infection such as the flu or a common cold.
Do not share ciprofloxacin with another person.
Store at room temperature away from moisture and heat. Do not allow the liquid medicine to freeze. Throw away any unused liquid after 14 days.
Take the medicine as soon as you can, but skip the missed dose if it is almost time for your next dose. Do not take two doses at one time.
Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.
Do not take ciprofloxacin with dairy products such as milk or yogurt, or with calcium- fortified juice. You may eat or drink these products with your meals, but do not use them alone when taking ciprofloxacin. They could make the medication less effective.
Using caffeine while taking ciprofloxacin can increase the effects of the caffeine.
Antibiotic medicines can cause diarrhea, which may be a sign of a new infection. If you have diarrhea that is watery or bloody, call your doctor before using anti-diarrhea medicine.
Ciprofloxacin could make you sunburn more easily. Avoid sunlight or tanning beds. Wear protective clothing and use sunscreen (SPF 30 or higher) when you are outdoors. Tell your doctor if you have severe burning, redness, itching, rash, or swelling after being in the sun.
Avoid driving or hazardous activity until you know how this medicine will affect you. Your reactions could be impaired.
Get emergency medical help if you have signs of an allergic reaction to ciprofloxacin (hives, difficult breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning in your eyes, skin pain, red or purple skin rash that spreads and causes blistering and peeling).
Ciprofloxacin can cause serious side effects, including tendon problems, side effects on your nerves (which may cause permanent nerve damage), serious mood or behavior changes (after just one dose), or low blood sugar (which can lead to coma).
Stop taking this medicine and call your doctor at once if you have:
low blood sugar - headache, hunger, sweating, irritability, dizziness, nausea, fast heart rate, or feeling anxious or shaky;
nerve symptoms in your hands, arms, legs, or feet - numbness, weakness, tingling, burning pain;
serious mood or behavior changes - nervousness, confusion, agitation, paranoia, hallucinations, memory problems, trouble concentrating, thoughts of suicide; or
signs of tendon rupture - sudden pain, swelling, bruising, tenderness, stiffness, movement problems, or a snapping or popping sound in any of your joints (rest the joint until you receive medical care or instructions).
In rare cases, ciprofloxacin may cause damage to your aorta, the main blood artery of the body. This could lead to dangerous bleeding or death. Get emergency medical help if you have severe and constant pain in your chest, stomach, or back.
Also, stop using this medicine and call your doctor at once if you have:
severe stomach pain, diarrhea that is watery or bloody;
fast or pounding heartbeats, fluttering in your chest, shortness of breath, and sudden dizziness (like you might pass out);
the first sign of any skin rash, no matter how mild;
muscle weakness, breathing problems;
little or no urination;
jaundice (yellowing of the skin or eyes); or
increased pressure inside the skull - severe headaches, ringing in your ears, dizziness, nausea, vision problems, pain behind your eyes.
Common ciprofloxacin side effects may include:
nausea, vomiting, diarrhea, stomach pain;
vaginal itching or discharge;
headache; or
abnormal liver function tests.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Some medicines can make ciprofloxacin much less effective when taken at the same time. If you take any of the following medicines, take your dose 2 hours before or 6 hours after you take the other medicine.
the ulcer medicine sucralfate, or antacids that contain calcium, magnesium, or aluminum (such as Maalox, Milk of Magnesia, Mylanta, Pepcid Complete, Rolaids, Tums, and others);
didanosine (Videx) powder or chewable tablets;
lanthanum carbonate or sevelamer; or
vitamin or mineral supplements that contain calcium, iron, magnesium, or zinc.
Tell your doctor about all your other medicines, especially:
cyclosporine, methotrexate, metoclopramide, phenytoin, probenecid, ropinirole, sildenafil, or theophylline;
a blood thinner (warfarin, Coumadin, Jantoven);
a diuretic or "water pill";
heart rhythm medication;
insulin or oral diabetes medicine (check your blood sugar regularly);
medicine to treat depression or mental illness;
steroid medicine (such as prednisone); or
NSAIDs (nonsteroidal anti-inflammatory drugsa>) - ibuprofen (Advil, Motrin), naproxen (Aleve), celecoxib, diclofenac, indomethacin, meloxicam, and others.
This list is not complete. Other drugs may interact with ciprofloxacin, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here.
Further informationRemember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use ciprofloxacin only for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.
Source: Drugs.com Ciprofloxacin Hydrochlori (www.drugs.com/ciprofloxacin.html).
Commonly reported side effects of ciprofloxacin include: pyelonephritis, arthralgia, and musculoskeletal signs and symptoms. Other side effects include: myalgia, and pain. See below for a comprehensive list of adverse effects.
For the ConsumerApplies to ciprofloxacin: oral powder for suspension, oral tablet
Other dosage forms:
Fluoroquinolones, including ciprofloxacin, are associated with disabling and potentially irreversible serious adverse reactions that have occurred together, including tendinitis and tendon rupture, peripheral neuropathy, and CNS effects. Discontinue ciprofloxacin and avoid use of fluoroquinolones in patients with these serious adverse reactions. Reserve use of ciprofloxacin for patients with no alternative treatment options for an uncomplicated UTI. Fluoroquinolones, including ciprofloxacin, may exacerbate muscle weakness in persons with myasthenia gravis. Avoid in patients with known history of myasthenia gravis.
Increased Risk of Aortic Aneurysm and Dissection After Fluoroquinolone Intake.
Systemic and inhaled fluoroquinolones may be associated with an increased risk of aortic aneurysm and dissection (especially in older patients).
Conditions predisposing to aortic aneurysm and dissection include: family history of aneurysm disease, preexisting aortic aneurysm and/or aortic dissection, other risk factors/conditions (e.g., Marfan syndrome, vascular Ehlers-Danlos syndrome, Takayasu arteritis, giant cell arteritis, Behcet's disease, hypertension, known atherosclerosis/peripheral atherosclerotic vascular diseases, elderly).
Recommendations:
Use fluoroquinolones in patients at risk for aortic aneurysm and dissection only after careful benefit/risk assessment and after other therapeutic options have been considered.
Avoid prescribing fluoroquinolones to patients with/at risk for aortic aneurysm; prescribe fluoroquinolones to such patients only when no other treatment options are available.
Advise patients to seek medical attention in an emergency department immediately if sudden-onset severe abdominal, chest, or back pain occurs; stop therapy at once if patient reports symptoms suggestive of aortic aneurysm or dissection.
Along with its needed effects, ciprofloxacin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking ciprofloxacin:
More common
Rare
Incidence not known
Some side effects of ciprofloxacin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Less common
For Healthcare Professionals
Applies to ciprofloxacin: intravenous solution, oral powder for reconstitution, oral tablet, oral tablet extended release
GeneralThe most common side effects (from clinical trials of all formulations, doses, durations of therapy, and indications) were nausea, diarrhea, abnormal liver function tests, vomiting, and rash. The most common side effects reported with the IV formulation were nausea, diarrhea, vomiting, injection and infusion site reactions, rash, and increased transaminases (transient).
GastrointestinalAntibiotic-associated colitis with possible fatal outcome was reported very rarely.
The onset of pseudomembranous colitis symptoms has been reported during or after antimicrobial treatment.
Common (1% to 10%): Nausea, diarrhea, vomiting, dyspepsia
Uncommon (0.1% to 1%): Abdominal pains/discomfort, gastrointestinal (GI) pains, flatulence
Rare (0.01% to 0.1%): Elevated amylase, antibiotic-associated colitis, pancreatitis
Frequency not reported: Clostridium difficile-associated diarrhea, constipation, GI bleeding, ileus, intestinal perforation, dry mouth, oral ulceration, epigastric pain, dysphagia, elevated lipase, painful oral mucosa, heartburn, acid reflux, aggravated irritable bowel syndrome, lower abdominal pain
Postmarketing reports: GI candidiasis, oral candidiasis, pseudomembranous colitis
DermatologicPhotosensitivity was seen most often when patients were exposed to intense sun (e.g., as when used to treat or prevent travelers' diarrhea).
A 27-year-old woman with mild systemic erythematosus developed toxic epidermal necrolysis (TEN) after starting a second oral course of this drug after a prior 5-day course. She developed a rash, high fever, and diarrhea after taking the 2nd dose and presented with diffuse rash, epidermal sloughing of 60% of the skin, desquamation of the lips, shock, and respiratory distress. She died on the 28th hospital day of TEN, right ventricular failure, and acute respiratory distress syndrome. As of 2003, 9 cases of TEN, including 5 fatalities, had been reported in the literature.
Erythema nodosum, Stevens-Johnson syndrome (potentially life-threatening), and TEN (potentially life-threatening) have also been reported during postmarketing experience.
Common (1% to 10%): Rash
Uncommon (0.1% to 1%): Pruritus, urticaria
Rare (0.01% to 0.1%): Angioedema, photosensitivity reactions, sweating/hyperhidrosis, petechiae, blistering
Very rare (less than 0.01%): Erythema multiforme, erythema nodosum, Stevens-Johnson syndrome (potentially life-threatening), toxic epidermal necrolysis (potentially life-threatening)
Frequency not reported: Exfoliative dermatitis, purpura, burning, phototoxicity reaction, dry skin, maculopapular rash, skin disorder, vesiculobullous rash, erythema, hyperpigmentation, cutaneous candidiasis, bullous pemphigoid, vesicles, lobular panniculitis, photoinduced acute exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms (DRESS)
Postmarketing reports: Acute generalized exanthematous pustulosis, fixed eruption
Nervous systemSeizures have been reported in 2 patients given this drug and foscarnet. The temporal association between the onset of seizures and drug administration suggests a possible drug interaction; causal relationship was not established in either case. Both drugs are individually epileptogenic; concurrent use may potentiate risk of seizures.
Cases of sensory or sensorimotor axonal polyneuropathy (affecting small and/or large axons) resulting in paresthesias, hypoesthesias, dysesthesias, and weakness have been reported.
One survey reported 11 cases of peripheral neuropathy associated with this drug. The severity ranged from mild and reversible to severe and persistent. In 1 case, a 44-year-old female developed numbness, allodynia, hypoesthesia, tremors, electrical and diffuse burning sensations, twitching, disorientation, visual impairment, nausea, temperature intolerance, rash, and palpitations; she remained disabled after 29 months.
Nystagmus, anosmia, hyperesthesia, hypoesthesia, hypertonia, intracranial hypertension, and exacerbation of myasthenia gravis have also been reported during postmarketing experience.
Common (1% to 10%): Headache, dizziness/lightheadedness, central nervous system disturbance
Uncommon (0.1% to 1%): Sleep disorders, taste disorders, seizures (including status epilepticus), dysesthesia, paresthesia, vertigo, hearing loss
Rare (0.01% to 0.1%): Syncope, hypoesthesia, tremor, tinnitus, migraine, olfactory nerve disorders, smell disorders, hearing impaired
Very rare (less than 0.01%): Disturbed coordination, intracranial hypertension, benign intracranial hypertension/pseudotumor cerebri, exacerbation of myasthenia gravis, hyperesthesia
Frequency not reported: Unresponsiveness, ataxia, hypertonia, anosmia, nystagmus, taste perversion/bad taste, somnolence/drowsiness, incoordination, disturbance in attention, dyskinesia, myasthenia gravis, paresis, aseptic meningitis, cerebral thrombosis, grand mal convulsion, dysphasia, lethargy, sensory axonal polyneuropathy, sensorimotor axonal polyneuropathy
Postmarketing reports: Taste loss, peripheral neuropathy (may be irreversible), polyneuropathy
HematologicPancytopenia (life-threatening or fatal outcome) and bone marrow depression (life-threatening) were reported very rarely; also reported during postmarketing experience.
Increased INR was reported in patients treated with vitamin K antagonists.
Common (1% to 10%): Eosinophilia
Uncommon (0.1% to 1%): Thrombocytopenia, thrombocythemia
Rare (0.01% to 0.1%): Leukopenia, anemia, neutropenia, leukocytosis, pancytopenia, bone marrow depression, abnormal prothrombin level
Very rare (less than 0.01%): Hemolytic anemia, agranulocytosis
Frequency not reported: Decreased hematocrit, decreased platelet counts, increased platelet counts, prolonged prothrombin time, decreased prothrombin, bleeding diathesis, decreased hemoglobin, decreased leukocyte count, increased atypical lymphocyte count, immature WBCs, increased blood monocytes, elevated sedimentation rate, elevated eosinophil counts, lymphadenopathy
Postmarketing reports: Methemoglobinemia, increased INR, prothrombin time prolonged or decreased
HepaticLiver necrosis very rarely progressed to life-threatening hepatic failure. Liver necrosis and hepatic failure (including fatal cases) have also been reported during postmarketing experience.
Common (1% to 10%): Abnormal liver function tests, increased transaminases
Uncommon (0.1% to 1%): Elevated bilirubin, hepatic impairment, cholestatic icterus/cholestatic jaundice, jaundice
Rare (0.01% to 0.1%): Hepatitis, liver necrosis
Very rare (less than 0.01%): Hepatic failure
Frequency not reported: Elevated AST, elevated ALT, elevated GGT
PsychiatricCommon (1% to 10%): Restlessness
Uncommon (0.1% to 1%): Psychomotor hyperactivity/agitation, confusion, disorientation, hallucinations
Rare (0.01% to 0.1%): Anxiety reaction, abnormal dreams, depression, psychotic reactions
Frequency not reported: Depersonalization, insomnia, manic reaction, nightmares, paranoia, phobia, toxic psychosis, nervousness, self-injurious behavior, suicidal ideations/thoughts, attempted suicide, completed suicide, catatonia, mania (including hypomania)
Postmarketing reports: Delirium
Depression and psychotic reactions (both potentially culminating in self-injurious behavior such as suicidal ideations/thoughts and attempted or completed suicide) have been reported.
Agitation, confusion, and toxic psychosis have also been reported during postmarketing experience.
GenitourinaryCrystalluria has been reported in patients with alkaline urine and did not necessarily lead to nephrotoxicity. At physiological urinary pH, the risk of crystalluria was considered minor.
Vaginal candidiasis has also been reported during postmarketing experience.
Common (1% to 10%): Vaginal candidiasis
Rare (0.01% to 0.1%): Hematuria, crystalluria
Frequency not reported: Albuminuria, cylindruria, frequent urination, hemorrhagic cystitis, vaginitis, dysmenorrhea, candiduria, polyuria, urethral bleeding, urinary retention, urinary tract infection, fungal vaginosis, bacterial vaginitis, dysuria, abnormal urine odor, female genital pruritus, vaginal infection, urinary frequency, micturition urgency, vaginal pruritus
LocalLocal IV site reactions occurred more often if the infusion time was 30 minutes or less. These reactions have appeared as local skin reactions and resolved quickly when infusion was completed.
Injection site irritation and induration have been reported with IV infusion time 30 minutes or less (instead of the recommended 1 hour) or when a small vein in the back of the hand was used.
Common (1% to 10%): Local IV site reactions, injection and infusion site reactions (e.g., phlebitis, thrombophlebitis)
Frequency not reported: Injection site irritation and induration with IV infusion
MusculoskeletalUncommon (0.1% to 1%): Musculoskeletal pain (e.g., extremity pain, back pain, chest pain), arthralgia
Rare (0.01% to 0.1%): Myalgia, arthritis, increased muscle tone and cramping, tendon rupture (mainly Achilles tendon)
Very rare (less than 0.01%): Tendinitis, muscular weakness
Frequency not reported: Arthropathy (including suspected reversible cases), joint stiffness, elevated serum creatine phosphokinase, abnormal joint exam, joint sprains, arthrosis, bone pain, decreased range of motion in a joint (knee, elbow, ankle, hip, wrist, shoulder), jaw pain, neck pain, gout flare-up, joint swelling, muscle spasms, night cramps, knee inflammation
Postmarketing reports: Myoclonus, myasthenia, twitching
Arthropathy has primarily been a concern in pediatric patients; however, at least 1 case was described in an adult cystic fibrosis patient receiving this drug. Although cystic fibrosis arthropathy and hypertrophic pulmonary osteoarthropathy typically occur in 7% to 8% of cystic fibrosis adults and adolescents, the arthropathy exhibited in this patient did not resemble either. Several elements in its presentation strongly supported the diagnosis of ciprofloxacin-induced arthropathy, such as: a consistent time of onset with other reported cases of suspected quinolone-induced arthropathy (usually 3 weeks after starting therapy); a lack of history of arthralgia in the patient; reoccurrence upon rechallenge; and resolution of symptoms upon discontinuation of therapy (usually 2 weeks after therapy stopped).
Tendinitis with subsequent tendon rupture has been documented in numerous case reports. One patient with chronic renal failure developed bilateral Achilles tendon rupture after 4 days of ciprofloxacin therapy. Although renal transplant patients and those with end-stage renal disease tend to have an increased risk of Achilles tendinitis and rupture over the general population, quinolone use has been shown to further increase that risk (12% in quinolone-treated patients versus 7% in nonquinolone-treated patients).
As of October 1994, 25 cases of Achilles tendon rupture had been reported to the US FDA. Some ruptures have also occurred in the hand or shoulder. Other risk factors identified included age and corticosteroid use.
There had been 23 reports of tendinitis submitted to the Australian Adverse Drug Reactions Committee (ADRAC) between 2006 and 2008, including reports of Achilles tendinitis, tendon rupture, and tendon pain and swelling. The reports were primarily in male patients (15 cases) older than 56 years who used this drug for 2 to 14 days. In 19 of the reported cases, a fluoroquinolone (generally ciprofloxacin) was the primary suspect; however, details of concomitant serious medical conditions were not documented in most of the reports.
Musculoskeletal side effects reported in pediatric patients included arthralgia, abnormal gait, abnormal joint exam, joint sprains, leg pain, back pain, arthrosis, bone pain, pain, myalgia, arm pain, and decreased range of motion in a joint (knee, elbow, ankle, hip, wrist, shoulder).
Myalgia, tendinitis, and tendon rupture have also been reported during postmarketing experience.
CardiovascularUncommon (0.1% to 1%): Tachycardia, vasodilatation, hypotension
Rare (0.01% to 0.1%): Vasculitis
Frequency not reported: Angina pectoris, cardiopulmonary arrest, myocardial infarction, hypertension, palpitation, bradycardia, arrhythmia, atrial flutter, cardiac murmur, cardiovascular collapse, ventricular ectopy, ventricular bigeminy, abdominal aortic bruit, postural hypotension
Postmarketing reports: QT prolongation/ECG QT prolonged, torsade de pointes, ventricular arrhythmia
Torsade de pointes was reported mainly in patients with risk factors for QT prolongation.
Vasculitis has also been reported during postmarketing experience.
OtherElevated serum theophylline has been reported in patients receiving theophylline concomitantly.
Gait disturbance and elevated serum potassium have also been reported during postmarketing experience.
Uncommon (0.1% to 1%): Candida infections, mycotic superinfections, pain, fever, malaise/feeling unwell, asthenia, edema
Very rare (less than 0.01%): Gait disturbance/abnormal gait
Frequency not reported: Irritability, flushing, thirst, elevated serum calcium, elevated serum potassium, elevated triglycerides, decreased serum albumin, decreased serum potassium, decreased total serum protein, elevated serum theophylline, serum phenytoin altered, chills, swelling, breast pain, achiness, weakness, fatigue, suprapubic pain, rigors, tenderness, fungal infection, increased body temperature
Postmarketing reports: Elevated serum cholesterol
MetabolicQuinolone class antibiotics have been associated with symptomatic hypoglycemia.
Uncommon (0.1% to 1%): Elevated blood alkaline phosphatase, decreased appetite/anorexia, decreased food intake
Rare (0.01% to 0.1%): Hyperglycemia, hypoglycemia
Frequency not reported: Elevated LDH, elevated uric acid, elevated blood glucose, decreased uric acid, decreased blood glucose, acidosis, symptomatic hypoglycemia
RenalUncommon (0.1% to 1%): Renal impairment, renal failure
Rare (0.01% to 0.1%): Tubulointerstitial nephritis
Frequency not reported: Elevated serum creatinine, renal calculi, elevated BUN, decreased BUN, abnormal kidney function, allergic interstitial nephritis, nephritis, myoglobin-associated acute kidney injury/failure
Allergic interstitial nephritis resulting in nonoliguric renal failure has been described in numerous case reports. Several cases included symptoms of rash, fever, and arthralgia and were accompanied by eosinophilia and eosinophiluria. Cases of allergic interstitial nephritis often responded to short courses of corticosteroid therapy.
OcularUncommon (0.1% to 1%): Visual disturbances (e.g., chromatopsia, diplopia, photopsia)
Very rare (less than 0.01%): Visual color distortions
Frequency not reported: Decreased visual acuity, blurred vision, cataracts, multiple punctate lenticular opacities, eye pain
Quinolone class antibiotics have been associated with cataracts and multiple punctate lenticular opacities.
HypersensitivityRare (0.01% to 0.1%): Allergic reactions, anaphylactic shock (life-threatening), allergic edema
Very rare (less than 0.01%): Anaphylactic reaction, serum sickness-like reaction
Frequency not reported: Anaphylactoid reactions, necrotizing vasculitis, cutaneous vasculitis
Allergic reactions ranged from urticaria to anaphylactic reactions, including life-threatening anaphylactic shock.
At least 2 cases have been reported of patients developing a cutaneous vasculitis related to use of this drug. The vasculitis resolved without medical intervention after the drug was discontinued.
Serum sickness-like reaction and anaphylactic shock (life-threatening) have also been reported during postmarketing experience.
RespiratoryRare (0.01% to 0.1%): Dyspnea (including asthmatic condition)
Frequency not reported: Bronchospasm, hemoptysis, laryngeal edema, respiratory arrest, epistaxis, hiccough, pulmonary edema, pleural effusion, pulmonary embolism, respiratory distress, wheeze, cough, upper respiratory tract infection, pharyngitis, nasopharyngitis
EndocrineFrequency not reported: Gynecomastia
ImmunologicFrequency not reported: Jarisch-Herxheimer reaction
Oral ciprofloxacin has been associated with a case of Jarisch-Herxheimer reaction (characterized by hypotension, tachycardia, and disseminated intravascular coagulation) in a 14-year-old female with tickborne relapsing fever.
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/1/2020.
Source: Drugs.com Ciprofloxacin Hydrochlori (www.drugs.com/ciprofloxacin.html).
November 24, 2020
December 2, 2020
November 15, 2020
December 2, 2020
December 1, 2020
October 19, 2020